Skip header and navigation

Refine By

1 records – page 1 of 1.

Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.

https://arctichealth.org/en/permalink/ahliterature146963
Source
Can J Cardiol. 2009 Dec;25(12):683-9
Publication Type
Article
Date
Dec-2009
Author
David Fitchett
John Eikelboom
Stephen Fremes
David Mazer
Steve Singh
Bindu Bittira
Stephanie Brister
John J Graham
Milan Gupta
Keyvan Karkouti
Agnes Lee
Michael Love
Rod McArthur
Mark Peterson
Subodh Verma
Terrence M Yau
Author Affiliation
St Michael's Hospital, Toronto, Canada. fichettd@smh.toronto.on.ca
Source
Can J Cardiol. 2009 Dec;25(12):683-9
Date
Dec-2009
Language
English
French
Publication Type
Article
Keywords
Acute Coronary Syndrome - drug therapy - surgery
Aspirin - therapeutic use
Canada
Coronary Artery Bypass - adverse effects
Drug Therapy, Combination
Health Planning Guidelines
Hemorrhage - chemically induced - prevention & control
Humans
Platelet Aggregation Inhibitors - therapeutic use
Risk factors
Societies, Medical
Ticlopidine - analogs & derivatives - therapeutic use
Treatment Outcome
Abstract
Acute coronary syndrome (ACS) guidelines recommend that most patients receive dual antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) at the time of presentation to prevent recurrent ischemic events. Approximately 10% of ACS patients require coronary artery bypass grafting surgery (CABG) during the index admission. Most studies show that patients who receive ASA and clopidogrel within five days of CABG have an increase in operative bleeding. Current consensus guidelines recommend discontinuation of clopidogrel therapy at least five days before planned CABG to reduce bleeding-related events. However, high-risk individuals may require urgent surgery without delay, to reduce the risk of potentially fatal ischemic events. The present multidisciplinary position statement provides evidence- based recommendations for the optimal use of dual antiplatelet therapy to balance ischemic and bleeding risks in patients with recent ACS who may require urgent CABG.
1. All ACS patients should be considered for dual antiplatelet therapy with ASA and clopidogrel at the earliest opportunity, despite the possibility of a need for urgent CABG. 2. For patients who have received clopidogrel and ASA, and require CABG: * Those at high risk of an early fatal event (eg, with refractory ischemia despite optimal medical treatment, and with high-risk coronary anatomy (eg, severe left main stenosis with severe right coronary artery disease), should be considered for early surgery without discontinuation of clopidogrel. * In patients with a high bleeding risk (eg, previous surgery, complex surgery) who are also at high risk for an ischemic event, consideration should be given to discontinuing clopidogrel for three to five days before surgery. * Patients at a lower risk for ischemic events (most patients) should have clopidogrel discontinued five days before surgery. 3. For patients who have CABG within five days of receiving clopidogrel and ASA, the risk of major bleeding and transfusion can be minimized by applying multiple strategies before and during surgery. 4. Patients who receive clopidogrel pre-CABG for a recent ACS indication should have clopidogrel restarted after surgery to decrease the risk of recurrent ACS. 5. For patients with a recent coronary stent, the decision to continue clopidogrel until the time of surgery or to discontinue will depend on the risk and potential impact of stent thrombosis. Restarting clopidogrel after CABG will depend on whether the stented vessel was revascularized, the type of stent and the time from stent implantation. Clopidogrel should be restarted when hemostasis is assured to prevent recurrent acute ischemic events.
Notes
Cites: Am Heart J. 2008 Dec;156(6):1080-1088.e119033002
Cites: Am Heart J. 2008 Nov;156(5):886-9219061702
Cites: JAMA. 2009 Mar 4;301(9):937-4419258584
Cites: J Thorac Cardiovasc Surg. 1996 May;111(5):1037-468622301
Cites: Circulation. 1998 Nov 3;98(18):1860-89799205
Cites: Eur Heart J. 2004 Nov;25(21):1903-1015522469
Cites: J Thorac Cardiovasc Surg. 2005 Feb;129(2):391-40015678051
Cites: J Cardiothorac Vasc Anesth. 2005 Feb;19(1):4-1015747262
Cites: Am Heart J. 2005 Feb;149(2):275-8315846265
Cites: Ann Thorac Surg. 2005 Sep;80(3):928-3316122457
Cites: JAMA. 2005 Sep 14;294(10):1224-3216143698
Cites: Ann Thorac Surg. 2005 Oct;80(4):1381-716181875
Cites: Ann Thorac Surg. 1995 Mar;59(3):664-77887708
Cites: Lancet. 2005 Nov 5;366(9497):1607-2116271642
Cites: J Am Coll Surg. 2006 Jan;202(1):131-816377506
Cites: Ann Thorac Surg. 2006 Mar;81(3):815-916488678
Cites: Diabetes. 2006 Mar;55(3):780-416505243
Cites: Heart. 2006 Apr;92(4):531-216537769
Cites: Ann Thorac Surg. 2006 May;81(5):1650-716631651
Cites: Crit Care Med. 2006 Jun;34(6):1608-1616607235
Cites: Ann Thorac Surg. 2006 Jul;82(1):13-2016798179
Cites: J Am Coll Cardiol. 2006 Jul 18;48(2):281-616843176
Cites: J Am Coll Cardiol. 2006 Sep 5;48(5):931-816949482
Cites: Ann Thorac Surg. 2006 Nov;82(5):1747-5617062241
Cites: Heart. 2007 Feb;93(2):177-8216757543
Cites: Circulation. 2007 Feb 13;115(6):813-817224480
Cites: Ann Thorac Surg. 2007 May;83(5 Suppl):S27-8617462454
Cites: Blood Coagul Fibrinolysis. 2007 Jul;18(5):461-517581321
Cites: Eur Heart J. 2007 Jul;28(13):1598-66017569677
Cites: Thromb Haemost. 2007 Jul;98(1):201-917598014
Cites: Circulation. 2007 Jul 31;116(5):471-917620512
Cites: J Thromb Thrombolysis. 2007 Oct;24(2):85-9117323134
Cites: J Am Coll Cardiol. 2007 Aug 14;50(7):e1-e15717692738
Cites: Arch Intern Med. 2007 Aug 13-27;167(15):1593-917698681
Cites: J Am Coll Cardiol. 2007 Oct 16;50(16):1541-717936152
Cites: N Engl J Med. 2007 Nov 15;357(20):2001-1517982182
Cites: Circulation. 2007 Nov 27;116(22):2544-5217998460
Cites: Circulation. 2008 Jan 29;117(4):478-8418172032
Cites: Pharmacotherapy. 2008 Mar;28(3):376-9218294117
Cites: N Engl J Med. 2008 Mar 20;358(12):1229-3918354101
Cites: Eur J Cardiothorac Surg. 2008 Jul;34(1):73-9218375137
Cites: J Am Coll Cardiol. 2008 Nov 18;52(21):1693-70119007688
Cites: Pharmacotherapy. 2008 Dec;28(12):1483-9419025429
Cites: Am Heart J. 2009 Apr;157(4):642-50.e119332190
Cites: N Engl J Med. 2009 May 14;360(20):2066-7819336502
Cites: J Am Coll Cardiol. 2009 May 26;53(21):1965-7219460609
Cites: N Engl J Med. 2009 Sep 10;361(11):1045-5719717846
Cites: Blood. 2000 Apr 15;95(8):2514-2210753829
Cites: Ann Thorac Surg. 2000 Sep;70(3):866-71; discussion 871-211016325
Cites: N Engl J Med. 2001 Jun 21;344(25):1879-8711419424
Cites: N Engl J Med. 2001 Aug 16;345(7):494-50211519503
Cites: Lancet. 2001 Aug 18;358(9281):527-3311520521
Cites: BMJ. 2002 Jan 12;324(7329):71-8611786451
Cites: Crit Care Med. 2001 Dec;29(12):2271-511801823
Cites: J Am Coll Cardiol. 2002 Jul 17;40(2):218-912106922
Cites: J Am Coll Cardiol. 2002 Jul 17;40(2):231-712106925
Cites: Circulation. 2002 Oct 22;106(17):2284-712390961
Cites: Stroke. 2002 Nov;33(11):2546-7; author reply 2546-712411639
Cites: JAMA. 2002 Nov 20;288(19):2411-2012435254
Cites: Am Heart J. 2003 Apr;145(4):595-60112679754
Cites: J Am Coll Cardiol. 2004 Aug 18;44(4):799-80315312862
Cites: Circulation. 2004 Sep 7;110(10):1202-815313956
Cites: J Thorac Cardiovasc Surg. 2004 Sep;128(3):425-3115354103
Cites: Circulation. 2004 Oct 5;110(14):e340-43715466654
Cites: N Engl J Med. 1983 Aug 18;309(7):396-4036135989
Cites: N Engl J Med. 1985 Nov 28;313(22):1369-753903504
Cites: Am J Cardiol. 1992 Jan 15;69(3):258-621731469
PubMed ID
19960127 View in PubMed
Less detail